Treats hypertension. ANDA 73665, held by Watson Laboratories. Atenolol; Chlorthalidone.
As of Nov 22, 2026, ANDA 73665 (Atenolol and Chlorthalidone), held by Watson Laboratories, was first approved by FDA on Jul 2, 1992, with 17 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Atenolol and chlorthalidone is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 2, 1992 | Original application | Approved | None posted |
| Atenolol and Chlorthalidone50MG;25MG · tablet;oral | Atenolol; Chlorthalidone | Rx |
| Atenolol and Chlorthalidone100MG;25MG · tablet;oral | Atenolol; Chlorthalidone | Rx |
| Jun 3, 2024 | Supplement 47Labeling · Standard review | Approved | None posted |
| Jun 11, 2015 | Supplement 39Labeling · Standard review | Approved | None posted |
| May 26, 2006 | Supplement 18Labeling | Approved | None posted |
| Mar 19, 2004 | Supplement 15Labeling | Approved | None posted |
| Apr 25, 2001 | Supplement 13Manufacturing | Approved | None posted |
| Apr 9, 2001 | Supplement 14Labeling | Approved | None posted |
| Aug 25, 2000 | Supplement 12Labeling | Approved | None posted |
| Jul 13, 2000 | Supplement 9Manufacturing | Approved | None posted |
| Sep 7, 1999 | Supplement 11Manufacturing | Approved | None posted |
| Sep 7, 1999 | Supplement 10Manufacturing | Approved | None posted |
| Jun 8, 1998 | Supplement 7Manufacturing | Approved | None posted |
| Jul 11, 1997 | Supplement 6Manufacturing | Approved | None posted |
| Nov 14, 1996 | Supplement 5Labeling | Approved | None posted |
| Jan 19, 1995 | Supplement 4Labeling | Approved | None posted |
| Feb 16, 1994 | Supplement 3Labeling | Approved | None posted |
| Jan 7, 1993 | Supplement 1Manufacturing | Approved | None posted |
| Nov 10, 1992 | Supplement 2Labeling | Approved | None posted |
| Jul 2, 1992 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters